Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial
Key PointsBlast-specific ex vivo venetoclax sensitivity correlated strongly with treatment responses and predicted longer survival.VenEx trial showed that